27 Oct PRODUCT MONOGRAPH. Pr. ACTEMRA. ® tocilizumab. 20 mg/mL Concentrate Solution for Infusion. mg/ mL Solution for Injection. 27 Oct Pronounced: ac-TEM-ra. This leaflet is part III of a three-part “Product ACTEMRA treatment should be initiated and supervised by specialist. Find valuable ACTEMRA® (tocilizumab) RA patient education information, including The majority resolved without any treatment and none necessitated drug.
|Published (Last):||11 November 2014|
|PDF File Size:||16.66 Mb|
|ePub File Size:||16.87 Mb|
|Price:||Free* [*Free Regsitration Required]|
An infection, think you may have an infection, are being treated for an infection, or get a lot of infections that return. These parts include the Ohio and Mississippi River Valleys and the Southwest Hepatitis B or have had hepatitis B Be sure to contact your healthcare provider or nurse if you see any signs of these side effects.
Actemra (tocilizumab) dose, indications, adverse effects, interactions from
Clinically relevant drug interactions may occur with CYP substrates that have a narrow therapeutic index such as cyclosporine. Do not use unused product remaining in vials; tocilizumab does not contain preservatives. Major Avoid using tocilizumab with other biological agents because of the possibility of insery immunosuppression and increased risk of infection.
Do not warm tocilizumab in any other way. ACTEMRA is an actekra, and treatment with immunosuppressants may result in an increased risk of malignancies.
The risks and benefits of treatment with ACTEMRA should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection. Promptly evaluate patients presenting with new-onset abdominal symptoms for early identification of GI perforation.
Major Avoid using tocilizumab with immunosuppressive biological agents such as pacakge because of the possibility of increased immunosuppression and increased risk of infection. Patients who receive tocilizumab are at increased risk for developing serious infections that may lead to hospitalization or death.
IL-6 is a proinflammatory cytokine that can insertt malaise, fatigue, and anemia. GI perforation risk may be increased with concurrent diverticulitis or concomitant use of NSAIDs or corticosteroid therapy. The concurrent use of tocilizumab with biological agens such as anti-CD20 monoclonal antibodies like ofatumumab has not been studied.
Assess lipid parameters approximately 4 to 8 weeks after tocilizumab initiation and subsequently at approximately 24 week intervals. In the 6-month control period, in SC-I, the frequency of injection-site reactions was Subcutaneous injection may subsequently be given by the patient or patient’s caregiver after proper training in actemga technique and a healthcare practitioner determines that it is appropriate.
Send the page ” ” to a friend, relative, colleague or yourself. Dosage modifications may be required. For example, the soluble IL-6 receptor can bind to IL-6 and can associate with gp to transduce the IL-6 signal into cells. Elevated transaminases have been noted acterma tocilizumab, and drug interruption or discontinuation may be needed.
Baricitinib may be used as monotherapy or concomitantly with methotrexate or other nonbiologic DMARDs. You may also call Genentech at A pregnancy registry has been established to monitor maternal and fetal outcomes; health care providers are encouraged to register pregnant women exposed to tocilizumab by calling Tocilizumab may have an effect on labor and obstetric delivery.
Your cholesterol levels should be checked 4 to 8 weeks after the start of your treatment, and then every 6 months after that. Tell your healthcare provider right away if you are experiencing any side effects. In the open-label ppackage over an average duration of 73 weeks of treatment, the overall rate of infections was per patient-years.
Acetaminophen; Chlorpheniramine; Dextromethorphan; Phenylephrine: Tocilizumab competes with IL-6 for binding to the IL-6 receptor. Two additional patients developed MAS pxckage the long-term extension. Based on animal data, there may be a potential risk to the fetus.
Among patients with a actmra weight of at least kg, the mean exposure values were higher than those inser the patient population. Administer the first injection of tocilizumab under the supervision of a qualified health professional.
Inser evaluating patients at risk for HBV and HCV infection for prior evidence of infection before tocilizumab initiation. In vitro, IL-6 induces osteoclast differentiation and activation. Neutrophils are white blood cells that help the body fight infection low platelet count.
ACTEMRA® (tocilizumab) RA, SJIA & PJIA References
ACTEMRA is an immunosuppressant, and treatment with immunosuppressants may result in an increased risk of malignancies. Anaphylaxis and other hypersensitivity reactions that required treatment discontinuation were reported in 0.
The half-life of tocilizumab is dependent on the concentration. Cautious use of tocilizumab may be warranted by patients with neurological disease such as preexisting or recent onset demyelinating disorders.
The effect of tocilizumab on CYP enzyme activity may persist for several weeks after stopping therapy In vitro, tocilizumab has the potential to affect expression of multiple CYP enzymes, including CYP3A4. In patients who develop an ANC less than per mm 3 treatment insfrt not recommended.
Tocilizumab may be used alone following discontinuation of glucocorticoids. Most patients taking tocilizumab who developed serious infections were taking concomitant immunosuppressives such as methotrexate.